{"entity":{"id":"hs-20117","kind":"drug","name":"HS-20117","aka":[],"tldr":"HS-20117 is an experimental bispecific antibody from Hansoh BioMedical R&D in phase 3 trials for non-small-cell lung cancer, aimed at EGFR and MET.","summary":"HS-20117 (PM1080) is a bispecific antibody developed by Hansoh BioMedical R&D. Its targets are EGFR and MET (the sponsor names EGFR x MET). The sponsor states: A fully-human EGFR-MET IgG1-like bispecific antibody. ClinicalTrials.gov describes the intervention as: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06417008 (A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT06417008, plans to enrol 1080 participants with primary completion was scheduled for 2026-06-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of HS-20117","url":"https://clinicaltrials.gov/search?intr=PM1080"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":[],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06417008"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PM1080","modality":"bispecific antibody","mechanism":"A fully-human EGFR-MET IgG1-like bispecific antibody.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hs-20117/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"trial":[{"id":"nct06417008","kind":"trial","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct06417008/"}]}}